Beovu (brolucizumab-dbll) - Novartis
Intraocular Inflammation following Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in Japanese Patients: Meta analysis using individual patient data (clinicaltrials.gov) - Sep 25, 2026 - P=N/A | N=1080 | Completed | Sponsor: Jichi Medical University | Unknown status ➔ Completed 
Trial completion • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
http://clinicaltrials.gov/ct2/show/UMIN000049461
 
Sep 25, 2026
 
Prev Next